Vericel CorpVCELEarnings & Financial Report
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
Revenue
$75.4M
Gross Profit
$58.5M
Operating Profit
$18.5M
Net Profit
$19.8M
Gross Margin
77.6%
Operating Margin
24.5%
Net Margin
26.3%
YoY Growth
16.0%
EPS
$0.40
Vericel Corp Q4 FY2024 Financial Summary
Vericel Corp reported revenue of $75.4M (up 16.0% YoY) for Q4 FY2024, with a net profit of $19.8M (up 52.4% YoY) (26.3% margin). Cost of goods sold was $16.9M, operating expenses totaled $40.0M.
Key Financial Metrics
| Total Revenue | $75.4M |
|---|---|
| Net Profit | $19.8M |
| Gross Margin | 77.6% |
| Operating Margin | 24.5% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
Vericel Corp Q4 FY2024 revenue of $75.4M breaks down across 2 segments, led by MACI Implants And Kits at $68.3M (90.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| MACI Implants And Kits | $68.3M | 90.7% |
| Other | $7.0M | 9.3% |
Vericel Corp Revenue by Segment — Quarterly Trend
Vericel Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as MACI Implants And Kits and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| MACI Implants And Kits | $84.1M | $55.7M | $53.5M | $46.3M |
| Other | $8.8M | $11.8M | $9.8M | $5.2M |
Vericel Corp Annual Revenue by Year
Vericel Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $276.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $276.3M |
| 2024 | $237.2M |
| 2023 | $197.5M |
| 2022 | $163.7M |
Vericel Corp Quarterly Revenue & Net Profit History
Vericel Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $92.9M | +23.3% | $23.2M | 25.0% |
| Q3 FY2025 | $67.5M | +16.6% | $5.1M | 7.5% |
| Q2 FY2025 | $63.2M | +20.1% | $-553.0K | -0.9% |
| Q1 FY2025 | $52.6M | +2.6% | $-11.2M | -21.4% |
| Q4 FY2024 | $75.4M | +16.0% | $19.8M | 26.3% |
| Q3 FY2024 | $57.9M | +27.0% | $-901.0K | -1.6% |
| Q2 FY2024 | $52.7M | +14.7% | $-4.7M | -8.9% |
| Q1 FY2024 | $51.3M | +25.0% | $-3.9M | -7.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51.3M | $52.7M | $57.9M | $75.4M | $52.6M | $63.2M | $67.5M | $92.9M |
| YoY Growth | 25.0% | 14.7% | 27.0% | 16.0% | 2.6% | 20.1% | 16.6% | 23.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $356.7M | $376.8M | $390.4M | $432.7M | $424.6M | $435.6M | $453.3M | $488.0M |
| Liabilities | $122.8M | $133.9M | $132.9M | $140.8M | $129.1M | $128.8M | $131.4M | $133.3M |
| Equity | $233.9M | $243.0M | $257.5M | $292.0M | $295.5M | $306.8M | $321.9M | $354.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $7.2M | $18.5M | $10.2M | $22.2M | $6.6M | $8.2M | $22.1M | $15.0M |